Every material Form 8-K PAVmed Inc. has filed with the SEC since August 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
PAVmed's subsidiary Lucid Diagnostics sold 15,000 shares of newly designated Series C Convertible Preferred Stock at $1,000 per share, raising gross proceeds of $15.0 million, with closing on the same day. The filing also discloses a registration rights agreement under which Lucid Diagnostics agreed to register resale of the common stock issuable on conversion, which could add shares to the market.
Subscription agreements dated effective October 21, 2026, with certain accredited investors
15,000 Series C Convertible Preferred shares sold at $1,000 per share; gross proceeds $15.0 million
Certificate of Designations filed in Delaware on the closing date; Lucid Diagnostics agreed to file a resale registration statement for underlying common stock
PAVmed Inc. signed a Sales Agreement with A.G.P./Alliance Global Partners that lets it sell common stock through the agent from time to time, up to $9,400,000 of shares under its current prospectus supplement. The company says it plans to use net proceeds for working capital and general corporate purposes, and the sales would dilute existing shareholders.
Maximum offering under the current prospectus supplement is $9,400,000 of common stock.
The agent's commission is 3.0% of aggregate gross sales prices, plus legal cost reimbursements of up to $65,000 at signing.
Shares are offered under a Form S-3 shelf registration declared effective April 15, 2025, with a prospectus supplement dated September 9, 2026.
Either party may terminate the agreement on ten business days' written notice.
PAVmed reported results for the quarter ended June 30, 2026, with a GAAP net loss attributable to common stockholders of $5.5 million, or $(0.87) per diluted share, compared with a loss of $13.3 million, or $(22.08) per share, a year earlier. The company also gave a business update on subsidiaries Lucid Diagnostics and Veris Health, including a first laboratory benefit manager coverage policy for EsoGuard.
GAAP net loss attributable to common stockholders was $5.5 million, or $(0.87) per diluted share, for the three months ended June 30, 2026, versus $13.3 million, or $(22.08) per share, a year earlier.
Non-GAAP adjusted loss was $1.7 million, or $(0.27) per share, for the quarter; cash and cash equivalents were $3.8 million as of June 30, 2026, up from $1.5 million at December 31, 2025.
Lucid Diagnostics recognized $1.5 million in EsoGuard revenue for the second quarter and processed 2,770 EsoGuard tests.
Veris Health is targeting an early 2027 FDA 510(k) submission for its implantable physiological monitor.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PAVmed Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →